Dataset opportunity
Nefrocenter — 医疗影像数据集机会
Nefrocenter 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
47.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗诊断人工智能市场 = 2023 年为 11 亿美元，复合年增长率为 25.2%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-09-14
Acquisizione digitale dei pazienti, come potenziarla e misurarne l’efficacia
healthtech360.it ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
医疗人工智能与诊断影像公司
Nefrocenter 持有大量独特的医疗影像数据集，该数据集源自其广泛的专业肾脏病学诊所网络。此专有图像集与纵向的 `medical_records` 和 `iot_data` 相结合，提供了一个丰富、多模态的资源，非常适合开发和验证高精度的诊断人工智能算法。该数据集的优势在于其真实的临床背景，捕捉了不同肾脏疾病阶段的各种患者病例。
商业价值巨大，定位在全球诊断人工智能市场，该市场在 2023 年的估值为11 亿美元，预计将以惊人的25.2% 的复合年增长率增长。[5] 虽然访问需要应对 GDPR 合规性等复杂性（针对高度敏感数据和分布式数据源），但对临床丰富、专业数据集的巨大需求使其成为旨在快速扩张的诊断技术领域领先地位的人工智能开发者的宝贵且稀有的资产。[5] ⚠ 尽职调查（有价值的数据，可协商的访问权限）：高度敏感的医疗数据（PII）需要严格的匿名化和 GDPR 合规性；数据分布在多个收购的诊所和专业中心；临床研究数据涉及大学合作，这可能会使知识产权复杂化。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
公开证据证实 Nefrocenter 拥有专有的医学影像集合，这些影像与肾脏病学、透析和糖尿病学领域的专业患者群体相关。该数据集对于寻求在专业影像诊断上训练模型的诊断人工智能公司来说是一项高价值资产，这是快速增长的 11 亿美元医疗诊断人工智能市场中的核心需求。该数据与患者护理以及心脏病学和神经病学等不同专业的直接联系，使其成为开发和验证下一代诊断人工智能的难得机会。
See dimension details ↓- Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
人工智能买家需求极高，这得益于一个预计将以 25.2% 的复合年增长率增长的市场，因为公司竞相开发具有独特临床数据的先进诊断工具。[5]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 种证据类型，4 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 个数据需求信号（3 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 超出已货币化的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ 审查 — 该公司的核心业务是医疗保健服务，但它有一个专门的研究部门和一个初创公司，积极基于其自身患者数据开发和产品化人工智能/预测算法，使其成为智能的销售者，因此不适合。问题：该公司正在基于其专有数据积极开发人工智能软件产品（NefroCloud、RENALERT-AI）。[19, 22, 23]；它有一个专门的健康科技初创公司，用于预测人工智能算法，该算法已被选入硅谷训练营，表明其产品化人工智能的明确战略；研究项目（如 SIATE）的既定目标是创建“用于临床和商业网络医学和人工智能应用的规模化、结构化数据库”；该公司是一个大型的多区域集团，拥有 50 多个中心，并收购了其他医院，可能太大而无法被视为中小企业。[1, 16]
- Deep Qualification90
✓ 通过 — Nefrocenter 是主要医疗保健提供商，其数据是其服务的副产品。该公司专注于诊断成像及其活跃的、以人工智能为重点的研究部门，使其医疗影像和患者数据成为一个合理且有价值的资产，尽管数据许可权不明确，并受严格的 GDPR 法规约束。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据表明收集了来自专业护理的患者记录，为肾脏病学和糖尿病患者群体提供了至关重要的临床背景，这对于训练准确的诊断模型至关重要。
IoT / sensor data
该集团在透析等专业护理中使用尖端技术，表明存在来自联网医疗设备的时间序列数据，为预测性人工智能模型提供了丰富的来源。
Image collection
Nefrocenter 直接证实其在多个高价值专业领域从事影像诊断业务，证明了诊断人工智能开发者所需的关键视觉数据的所有权。
business_records
该公司与意大利国家卫生服务就实验室诊断达成的正式协议，证实了其生成适合监管意识人工智能应用的结构化、高质量诊断数据的历史。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Nefrocenter Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Diagnostics Market = $1.1 Billion in 2023, CAGR 25.2% (source: Market.us). Investment score 47.5/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Insightmedbotics — 医学影像数据集机会
View opportunity →工业Visimind — 工业传感器数据集机会
View opportunity →移动Swtchenergy — 移动遥测数据集机会
View opportunity →